Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 11/20 | 0.76 |
| ▸ | EP300 | Q09472 | 3/20 | 0.72 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.72 |
| ▸ | KAT2A | Q92830 | 3/20 | 0.72 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | MMP10 | P09238 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17515276 | 0.85 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2ACASP3 | |
| SCHEMBL18872059 | 0.84 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2ACASP3 | |
| SCHEMBL17502095 | 0.84 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2ACASP3 | |
| SCHEMBL18503655 | 0.80 | HDAC3 (0.76) | KAT2BEP300CREBBPKAT2ACASP3 | |
| SCHEMBL29711779 | 0.80 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2ACASP3 | |
| SCHEMBL20771543 | 0.80 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2ACASP3 | |
| SCHEMBL17515279 | 0.79 | CASP3 (1.00) | CASP3HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL29798990 | 0.79 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL26964488 | 0.79 | KAT2B (1.00) | KAT2BEP300CREBBPKAT2AMMP10 | |
| SCHEMBL18492996 | 0.77 | HDAC6 (1.00) | KAT2BEP300CREBBPKAT2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136030-A1 | TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE NON-MEVALONATE PATHWAY | WASHINGTON UNIVERSITY (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136030-A1 | TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE NON-MEVALONATE PATHWAY | WASHINGTON UNIVERSITY (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160046651-A1 | TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE NON-MEVALONATE PATHWAY | UNIV WASHINGTON (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046651-A1 | TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE NON-MEVALONATE PATHWAY | UNIV WASHINGTON (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046651-A1 | TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE NON-MEVALONATE PATHWAY | IMPDH1, IMPDH2, SHMT2 | KAT2B 4565/4885EP300 3342/4885CREBBP 2218/4885 |
| US-20170136030-A1 | TREATMENT OF MALARIA USING INHIBITORS OF THE ISPD ENZYME IN THE NON-MEVALONATE PATHWAY | IMPDH1, IMPDH2, SHMT2 | KAT2B 4565/4885EP300 3342/4885CREBBP 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.